ARTICLE | Company News
Calibrant, The Cleveland Clinic deal
February 4, 2008 8:00 AM UTC
The parties will use Calibrant’s Gemini proteomics platform to identify prognostic biomarkers and therapeutic targets from glioblastoma multiforme (GBM) samples provided by the clinic. Ownership of re...